A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

NCT02195479 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

706

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Velcade
DRUG: Melphalan
DRUG: Prednisone
DRUG: Daratumumab IV
DRUG: Dexamethasone
DRUG: Daratumumab SC

Sponsor

Janssen Research & Development, LLC